Andrea S. Blevins Primeau, PhD, MBA

The optimal sequence of treatment for BRAF-mutant melanoma is nivolumab-ipilimumab followed by dabrafenib-trametinib, a study suggests.

Switching treatment from a first-line aromatase inhibitor plus palbociclib to fulvestrant plus palbociclib upon detection of a rising ESR1 mutation in the blood improved progression-free survival in patients with HER2-negative advanced breast cancer.

Researchers sought to determine whether a lack of response to tisagenlecleucel had a link with survival in patients with B-ALL.

Chemotherapy does not improve long-term outcomes in patients with early-stage invasive lobular carcinoma, according to a meta-analysis.

The aim of this trial was to evaluate the efficacy and safety of orelabrutinib with RCHOP in patients with extranodal non-GCB DLBCL.

Adding liposomal irinotecan to 5-fluorouracil and leucovorin can improve outcomes in gemcitabine-refractory, advanced pancreatic cancer, a phase 3 study suggests.

Researchers sought to determine whether tisagenlecleucel was effective would be effective in infant patients with B-ALL

MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.

Adding pembrolizumab to chemoradiotherapy did not improve event-free survival or overall survival.

Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.